Literature DB >> 21479837

Vertebral fractures in males with prolactinoma.

Gherardo Mazziotti1, Teresa Porcelli, Marilda Mormando, Ernesto De Menis, Antonio Bianchi, Carola Mejia, Tatiana Mancini, Laura De Marinis, Andrea Giustina.   

Abstract

Data on osteoporotic fractures in hyperprolactinemia are limited. An increased prevalence of radiological vertebral fractures was recently observed in women with prolactin (PRL)-secreting adenoma, whereas it is unknown whether this observation may reflect a more general increased risk of fractures in this disease and whether the prevalence of fractures in males is affected by gonadal status. Thirty-two males (median age 47 years, range: 22-79) with PRL-secreting pituitary adenoma (10 with microadenoma and 22 with macroadenoma) and 64 control males, with normal PRL values and with comparable age to patients with hyperprolactinemia, were evaluated for vertebral fractures by a morphometric approach and for bone mineral density (BMD) by a dual-energy X-ray absorptiometry at lumbar spine. Vertebral fractures were shown in 12 patients with PRL-secreting adenoma (37.5%) and in 5 controls (7.8%, P < 0.001). Fractured patients had lower BMD T-score (P = 0.007) and longer duration of disease (P < 0.001) as compared to patients who did not fracture. Fractures occurred more frequently (P = 0.03) in patients with untreated hyperprolactinemia versus patients treated with cabergoline whose frequency of vertebral fractures was still higher than control subjects. The prevalence of vertebral fractures was not significantly different between eugonadal and hypogonadal patients (33.3% vs. 38.5%; P = 0.8). Moreover, no significant (P = 0.4) difference in serum testosterone values was found between fractured and not fractured males. Hyperprolactinemia is associated with high prevalence of radiological vertebral fractures in men with PRL-secreting adenoma. These findings would also suggest that PRL excess may produce negative skeletal effects independently of hypogonadism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479837     DOI: 10.1007/s12020-011-9462-5

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  36 in total

Review 1.  Current guidelines for adult GH replacement.

Authors:  Mauro Doga; Stefania Bonadonna; Monica Gola; Sebastiano Bruno Solerte; Giovanni Amato; Carlo Carella; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

2.  Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.

Authors:  A Colao; C Di Somma; S Loche; A Di Sarno; M Klain; R Pivonello; M Pietrosante; M Salvatore; G Lombardi
Journal:  Clin Endocrinol (Oxf)       Date:  2000-03       Impact factor: 3.478

Review 3.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

Review 4.  Glucocorticoid-induced osteoporosis: an update.

Authors:  Gherardo Mazziotti; Alberto Angeli; John P Bilezikian; Ernesto Canalis; Andrea Giustina
Journal:  Trends Endocrinol Metab       Date:  2006 May-Jun       Impact factor: 12.015

Review 5.  Treatment of pituitary tumors: dopamine agonists.

Authors:  Gabriella Iván; Nikoletta Szigeti-Csúcs; Márk Oláh; György M Nagy; Miklós I Góth
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 6.  The effects of hyperprolactinemia on bone and fat.

Authors:  Amal Shibli-Rahhal; Janet Schlechte
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

7.  Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism.

Authors:  S L Greenspan; D S Oppenheim; A Klibanski
Journal:  Ann Intern Med       Date:  1989-04-01       Impact factor: 25.391

8.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

9.  Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group.

Authors:  H K Genant; M Jergas; L Palermo; M Nevitt; R S Valentin; D Black; S R Cummings
Journal:  J Bone Miner Res       Date:  1996-07       Impact factor: 6.741

10.  Bone density in amenorrheic women with and without hyperprolactinemia.

Authors:  J A Schlechte; B Sherman; R Martin
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

View more
  30 in total

1.  Editorial: is macroprolactinemia just a diagnostic pitfall?

Authors:  Marcello D Bronstein
Journal:  Endocrine       Date:  2012-04       Impact factor: 3.633

2.  Antipsychotics and osteoporosis: current awareness and practice in primary care.

Authors:  Ernesto Jones
Journal:  Br J Gen Pract       Date:  2014-11       Impact factor: 5.386

Review 3.  Acromegalic osteopathy.

Authors:  G Mazziotti; F Maffezzoni; S Frara; A Giustina
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

Review 5.  Treatment of hyperprolactinemia in post-menopausal women: pros.

Authors:  D Iacovazzo; L De Marinis
Journal:  Endocrine       Date:  2014-08-12       Impact factor: 3.633

6.  Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.

Authors:  Serap Soytac Inancli; Alper Usluogullari; Yusuf Ustu; Sedat Caner; Abbas Ali Tam; Reyhan Ersoy; Bekir Cakir
Journal:  Endocrine       Date:  2012-12-12       Impact factor: 3.633

7.  Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.

Authors:  Aysegul Atmaca; Birsen Bilgici; Gulcin Cengiz Ecemis; Ozgur Korhan Tuncel
Journal:  Endocrine       Date:  2013-03-26       Impact factor: 3.633

8.  Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience.

Authors:  G Mazziotti; A M Formenti; M B Panarotto; E Arvat; A Chiti; A Cuocolo; M E Dottorini; C Durante; L Agate; S Filetti; F Felicetti; A Filice; L Pace; T Pellegrino; M Rodari; M Salvatori; C Tranfaglia; A Versari; D Viola; S Frara; A Berruti; A Giustina; R Giubbini
Journal:  Endocrine       Date:  2017-11-06       Impact factor: 3.633

Review 9.  Osteoporosis in men: recent progress.

Authors:  Robert A Adler
Journal:  Endocrine       Date:  2013-01-25       Impact factor: 3.633

10.  Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection.

Authors:  T Porcelli; D Gotti; A Cristiano; F Maffezzoni; G Mazziotti; E Focà; F Castelli; A Giustina; E Quiros-Roldan
Journal:  Osteoporos Int       Date:  2014-07-24       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.